EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis

Ruziye Erol Yildiz iD, Ece Akbayir iD, Tuğçe Kizilay iD, Ayça Simay Ersöz iD, Duygu Özkan Yaşargün iD, Devran Süer iD, Vuslat Yilmaz iD, Erdem Tüzün iD, Recai Türkoğlu iD

Turkish Journal of Medical Sciences · 14.10.2025 · 55 (5) · 1122-1129

DOI: 10.55730/1300-0144.6067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 14.10.2025. Verfasst von Ruziye Erol Yildiz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkiye. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Neurofilament Proteins, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: Patients with multiple sclerosis (MS) may present with a rapidly disabling clinical course in the first few years of disease. It is imperative to find biomarkers to predict patients with aggressive MS (AMS) and have an opportunity to prevent disability accumulation through appropriate treatment strategies. Our aim was to explore the prognostic value of neurofilament light chain (NFL) and brain-derived neurotrophic factor (BDNF) levels in cerebrospinal fluid (CSF) obtained in the early stages of MS. Materials and methods: Relapsing-remitting multiple sclerosis (RRMS) patients presenting with first-time attacks were screened, of which 26 fulfilled AMS criteria in the 3-year follow-up period. In addition, 27 age/sex-matched RRMS patients without AMS (non- AMS) were included. Baseline NFL and BDNF levels were measured in CSF obtained during the remission period following the first MS attack. Disease activity was monitored for 3 years by periodic expanded disability status scale (EDSS), cranial-spinal MRI assessments, and no evidence of disease activity (NEDA)-3 was determined.

Results

AMS patients showed significantly higher attack numbers, EDSS scores, MRI lesions, and baseline NFL levels compared to non-AMS patients. Baseline BDNF levels were significantly lower than in non-AMS patients. NFL/BDNF levels were correlated with number of attacks and/or EDSS scores at the third year follow-up. Patients with NEDA-3 showed significantly lower baseline NFL and higher BDNF levels than those without NEDA-3. Receiver operating characteristic curve analysis showed the highest specificity for CSF BDNF measurements in predicting AMS conversion.

Conclusion

Baseline NFL and BDNF levels effectively predict the development of AMS emerging early in the course of MS. Combined use of these molecular markers with MRI results may enable early diagnosis and appropriate therapeutic intervention of AMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorNeurofilament ProteinsMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisHumansFemaleMaleAdultBiomarkersPrognosisMiddle AgedMagnetic Resonance Imaging

Stichwörter der Autor:innen

Multiple sclerosisautoimmunitybrain-derived neurotrophic factordisabilityneurofilament light chain

Substanzen

Brain-Derived Neurotrophic FactorNeurofilament Proteinsneurofilament protein LBiomarkersBDNF protein, human

Autor:innen und Institutionen

  • Department of Neurology, University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkiye.
  • Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, Turkiye.
  • Department of Language and Speech Therapy, Faculty of Health Sciences, İstanbul Atlas University, İstanbul, Turkiye.

ORCID-Profile: Ruziye Erol Yildiz, Ece Akbayir, Tuğçe Kizilay, Ayça Simay Ersöz, Duygu Özkan Yaşargün, Devran Süer, Vuslat Yilmaz, Erdem Tüzün, Recai Türkoğlu

Zitieren

APA

Erol Yildiz, R., Akbayir, E., Kizilay, T., Ersöz, A. S., Özkan Yaşargün, D., Süer, D., Yilmaz, V., Tüzün, E., & Türkoğlu, R. (2025). Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis. Turkish Journal of Medical Sciences, 55(5), 1122-1129. https://doi.org/10.55730/1300-0144.6067

Vancouver

Erol Yildiz R, Akbayir E, Kizilay T, Ersöz AS, Özkan Yaşargün D, Süer D, et al. Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis. Turkish Journal of Medical Sciences. 2025;55(5):1122-1129. doi:10.55730/1300-0144.6067

BibTeX
@article{ErolYildiz2025,
  author = {Erol Yildiz, Ruziye and Akbayir, Ece and Kizilay, Tuğçe and Ersöz, Ayça Simay and Özkan Yaşargün, Duygu and Süer, Devran and Yilmaz, Vuslat and Tüzün, Erdem and Türkoğlu, Recai},
  title = {Baseline neurofilament light chain and brain-derived neurotrophic factor levels predict development of aggressive multiple sclerosis},
  journal = {Turkish Journal of Medical Sciences},
  year = {2025},
  volume = {55},
  number = {5},
  pages = {1122--1129},
  doi = {10.55730/1300-0144.6067}
}
Kostenlos starten →